IL192372A0 - Inhibition of cxcr4 and/or cell motility - Google Patents

Inhibition of cxcr4 and/or cell motility

Info

Publication number
IL192372A0
IL192372A0 IL192372A IL19237208A IL192372A0 IL 192372 A0 IL192372 A0 IL 192372A0 IL 192372 A IL192372 A IL 192372A IL 19237208 A IL19237208 A IL 19237208A IL 192372 A0 IL192372 A0 IL 192372A0
Authority
IL
Israel
Prior art keywords
cxcr4
inhibition
cell motility
motility
cell
Prior art date
Application number
IL192372A
Original Assignee
Yeda Res & Dev
Fridkin Mati
Shivtiel Shoham
Asaf Spiegel
Lapidot Tsvee
Rubinstein Menachem
Kalinkovich Alexander
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev, Fridkin Mati, Shivtiel Shoham, Asaf Spiegel, Lapidot Tsvee, Rubinstein Menachem, Kalinkovich Alexander filed Critical Yeda Res & Dev
Priority to IL192372A priority Critical patent/IL192372A0/en
Publication of IL192372A0 publication Critical patent/IL192372A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL192372A 2005-12-29 2008-06-22 Inhibition of cxcr4 and/or cell motility IL192372A0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL192372A IL192372A0 (en) 2005-12-29 2008-06-22 Inhibition of cxcr4 and/or cell motility

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL172896A IL172896A0 (en) 2005-12-29 2005-12-29 Cxcr4 inhibition
PCT/IL2006/001494 WO2007074456A2 (en) 2005-12-29 2006-12-27 Inhibition of cxcr4 and/or cell motility by phenylalanine, cysteine or peptides containing said aminoacids
IL192372A IL192372A0 (en) 2005-12-29 2008-06-22 Inhibition of cxcr4 and/or cell motility

Publications (1)

Publication Number Publication Date
IL192372A0 true IL192372A0 (en) 2008-12-29

Family

ID=38093072

Family Applications (2)

Application Number Title Priority Date Filing Date
IL172896A IL172896A0 (en) 2005-12-29 2005-12-29 Cxcr4 inhibition
IL192372A IL192372A0 (en) 2005-12-29 2008-06-22 Inhibition of cxcr4 and/or cell motility

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL172896A IL172896A0 (en) 2005-12-29 2005-12-29 Cxcr4 inhibition

Country Status (6)

Country Link
EP (1) EP1971356A2 (en)
JP (1) JP2009521917A (en)
AU (1) AU2006329534A1 (en)
CA (1) CA2635770A1 (en)
IL (2) IL172896A0 (en)
WO (1) WO2007074456A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010066858A1 (en) * 2008-12-10 2010-06-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment and the prognosis of cancer
US9155780B2 (en) 2009-02-11 2015-10-13 Yeda Research And Development Co. Ltd. Short beta-defensin-derived peptides
CA2779161A1 (en) * 2009-10-28 2011-05-05 University Of Manitoba Yellow pea seed protein-derived peptides
ES2670969T3 (en) 2012-11-13 2018-06-04 Adocia Fast-acting insulin formulation comprising a substituted anionic compound
US9795678B2 (en) 2014-05-14 2017-10-24 Adocia Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
FR3020947B1 (en) 2014-05-14 2018-08-31 Adocia AQUEOUS COMPOSITION COMPRISING AT LEAST ONE PROTEIN AND A SOLUBILIZING AGENT, ITS PREPARATION AND ITS USES
FR3043557B1 (en) 2015-11-16 2019-05-31 Adocia RAPID ACID COMPOSITION OF INSULIN COMPRISING A SUBSTITUTED CITRATE
EP3773909A1 (en) * 2018-03-29 2021-02-17 Université Paris Est Créteil Val De Marne Phenylalanine derivatives for use in the treatment of cancers
DE102020201019A1 (en) * 2020-01-29 2021-07-29 Beiersdorf Aktiengesellschaft Allergen protection for the skin
CN111574597B (en) * 2020-05-07 2023-03-31 中国科学院微生物研究所 anti-HIV polypeptide modified by high molecular weight PEG (polyethylene glycol), preparation method and application thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01146817A (en) * 1987-12-02 1989-06-08 Norio Shimura Agent for alleviating acquired immune deficiency syndrome
FR2657259A1 (en) * 1990-01-25 1991-07-26 Adir USE OF N-MYRISTOYL- (S) -PHENYLALANINE FOR THE PRODUCTION OF MEDICAMENTS FOR THE TREATMENT OF DISEASES INVOLVING MYRISTOYLATION
US5977073A (en) * 1991-06-06 1999-11-02 Life Sciences' Technologies, Inc. Nutrient composition for treatment of immune disorders
US20040121952A1 (en) * 1997-05-21 2004-06-24 Children's Medical Center Corporation Treatment of cancer
DE19734161A1 (en) * 1997-08-07 1999-04-01 Jerini Biotools Gmbh Antagonists of stroma cell-derived factor-1, for diagnosis and treatment of human immune deficiency virus (HIV) infection
US6251868B1 (en) * 1998-04-30 2001-06-26 Teijin Limited Method for treating a human immunodeficiency virus infection
US6103748A (en) * 1998-06-19 2000-08-15 Bryan; Thomas B. Method of treating an autoimmune disorder
EP1004302A3 (en) * 1998-10-29 2003-06-04 Ajinomoto Co., Inc. Immunomodulator
MXPA01008178A (en) * 1999-02-18 2002-03-13 Hoffmann La Roche Phenylalaninol derivatives.
US20020155468A1 (en) * 1999-09-23 2002-10-24 Corixa Corporation Ovarian tumor antigen and methods of use therefor
WO2001085196A2 (en) * 2000-05-09 2001-11-15 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
US6337317B1 (en) * 2000-06-27 2002-01-08 The University Of British Columbia Antimicrobial peptides and methods of use thereof
MY129000A (en) * 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
US20020147206A1 (en) * 2001-04-05 2002-10-10 Pfizer Inc. Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy
KR20030021857A (en) * 2001-09-08 2003-03-15 주식회사 에코윈 Anticancerigenic Agent Including Copper(Ⅱ) Aminoacidate 1:1 Complex And Method Of Preparing The Same
US7892559B2 (en) * 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
DE10225144A1 (en) * 2002-05-29 2003-12-18 Immatics Biotechnologies Gmbh Tumor-associated peptides binding to MHC molecules
EP1371660A1 (en) * 2002-06-14 2003-12-17 Consejo Superior De Investigaciones Cientificas Vaccine
US7183258B2 (en) * 2002-06-19 2007-02-27 Lipps Binie V Two synthetic peptides for treatment and prevention of cancers
US7329486B2 (en) * 2003-03-31 2008-02-12 The Board Of Regents Of The University Of Texas System High-throughput assay for virus entry and drug screening
US20040247686A1 (en) * 2003-04-04 2004-12-09 Boehringer Ingelheim International Gmbh Pharmaceutical compositions comprising epinastine for the treatment of skin diseases
EP1589030A1 (en) * 2004-04-14 2005-10-26 Friedrich-Alexander-Universität Erlangen-Nürnberg Bob-1 specific T cells and methods to use
CA2597191C (en) * 2005-02-09 2014-04-01 Helix Biomedix Inc. Antimicrobial hexapeptides
WO2007004613A1 (en) * 2005-07-01 2007-01-11 Ajinomoto Co., Inc. THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASE AND TNF-α PRODUCTION INHIBITOR

Also Published As

Publication number Publication date
AU2006329534A1 (en) 2007-07-05
EP1971356A2 (en) 2008-09-24
WO2007074456A3 (en) 2008-05-29
CA2635770A1 (en) 2007-07-05
JP2009521917A (en) 2009-06-11
IL172896A0 (en) 2006-06-11
WO2007074456A2 (en) 2007-07-05

Similar Documents

Publication Publication Date Title
IL192372A0 (en) Inhibition of cxcr4 and/or cell motility
EP1951736A4 (en) Multitargeting interfering rnas and methods of their use and design
EP1909644A4 (en) Inserter and methods of use
IL177540A0 (en) Analysis of cell morphology and motility
EP1945137A4 (en) Partially covered stent devices and methods of use
EP1962892A4 (en) Inhibition of cell proliferation
PL1859004T3 (en) Well treatment composition crosslinkers and uses thereof
EP1879659A4 (en) Low-irritation compositions and methods of making the same
EP1919977A4 (en) Poly (block-phosphonato-ester) and poly (block-phosphonato-carbonate) and methods of making same
IL229039A0 (en) Solid compositions and methods for treating middle-of-the night insomnia
IL189609A0 (en) 4-substituted pyrrolidin-2-ones and their use
EP1940787A4 (en) Novel ido inhibitors and methods of use thereof
EP1942947A4 (en) Fibronectin polypeptides and methods of use
IL187821A0 (en) Unsolvated benzodiazepine compositions and methods
IL187463A0 (en) Proteasome inhibitors and uses thereof
EP1951682A4 (en) Novel 2-aminopyrimidinone or 2-aminopyridinone derivatives and their use
EP1928496A4 (en) C/clp antagonists and methods of use thereof
IL189252A0 (en) Dihydroxyanthraquinones and their use
IL184731A0 (en) Mucin hypersecretion inhibitors based on the structure of mans and methods of use
HK1114641A1 (en) Activating agent of stem cells and or progenitor cells
ZA200710205B (en) Solid compositions and methods for treating middle-of-the night insomnia
GB0520930D0 (en) Composition and method of use
IL177444A0 (en) Analogs exhibiting inhibition of cell proliferation, methods of making, and uses thereof
GB0504657D0 (en) Compositions and methods of treatment
EP1978999A4 (en) Isolated mcpip and methods of use